Engineering Next-Generation CAR-T: Dual & Triple Targeting Strategies for Superior Clinical Outcomes

• Developing a dual-target CAR-T therapy for AML aimed at overcoming antigen heterogeneity and antigen escape–driven relapse
• Sharing insights about GPC3-targeted, multi-modal CAR-T therapy for hepatocellular carcinoma (HCC) to overcome the immunosuppressive tumor microenvironment, enhance T-cell persistence and infiltration, recruit endogenous bystander T cells

Speakers:

Jeonghoon Han

Chief Executive Officer

Cunnovative